Abstract

Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), a multifunctional cytokine, is regulated by different factors including degree of cell differentiation, hypoxia, and certain oncogenes namely, ras and src. The up-regulation of VPF/VEGF expression by Ras has been found to be through both transcription and mRNA stability. The present study investigates a novel pathway whereby Ras promotes the transcription of VPF/VEGF by activating protein kinase Czeta (PKCzeta). The Ras-mediated overexpression of VPF/VEGF was also found to be inhibited by using the antisense or the dominant-negative mutant of PKCzeta. In co-transfection assays, by overexpressing oncogenic Ha-Ras (12 V) and PKCzeta, there was an additive effect up to 4-fold in activation of Sp1-mediated VPF/VEGF transcription. It has been shown through electrophoretic mobility shift assay that Ras promoted the PKCzeta-induced binding of Sp1 to the VPF/VEGF promoter. In the presence of PDK-1, a major activating kinase for PKC, the Ras-mediated activation of VPF/VEGF promoter through PKCzeta was further increased, suggesting that PKCzeta can serve as an effector for both Ras and PDK-1. In other experiments, with the use of a dominant-negative mutant of phosphatidylinositol 3-kinase, the activation of VPF/VEGF promoter through Ras, PDK-1, and PKCzeta was completely repressed, indicating phosphatidylinositol 3-kinase as an important component of this pathway. Taken together, these data elucidate the signaling mechanism of Ras-mediated VPF/VEGF transcriptional activation through PKCzeta and also provide insight into PKCzeta and Sp1-dependent transcriptional regulation of VPF/VEGF.

Highlights

  • The growth and metastasis of tumors depend on the development of an adequate blood supply via angiogenesis which is attributed in large part to the production of angiogenesis promoting growth factors by tumor [1, 2]

  • protein kinase C (PKC)␨, an Intermediary Molecule for Ras-mediated Overexpression of VPF/VEGF—In the present study we demonstrate that oncogene Ha-Ras(G12V) promoted the Sp1-mediated VPF/ VEGF transcriptional activation in human fibrosarcoma (HT1080) and renal cell carcinoma (786-0) cell lines (Fig. 1). 786-0 and HT1080 cells were co-transfected with a 2.6-kb VPF/ VEGF promoter-luciferase construct and plasmid containing Ha-Ras(G12V)

  • To elucidate the role of PKC␨ in Ras-mediated VPF/VEGF overexpression, we studied the effect of the dominant-negative mutant and the antisense (AS) oligonucleotide of PKC␨ on the expression of VPF/VEGF mRNA in HT1080 and 786-0 cells

Read more

Summary

Introduction

The growth and metastasis of tumors depend on the development of an adequate blood supply via angiogenesis which is attributed in large part to the production of angiogenesis promoting growth factors by tumor [1, 2]. VPF/VEGF is overexpressed by a wide variety of human tumors and plays a critical role in tumorigenesis. Constitutively expressed by many tumor cells, VPF/VEGF expression is substantially up-regulated by hypoxia, cytokines, hormones, and certain oncogenes including activated forms of src and ras [5,6,7]. We have recently shown that protein kinase signaling pathways play an important role in tumor angiogenesis [8, 9]. Among the protein kinase C (PKC) family, the isoform PKC␨ plays a critical role in regulating VPF/VEGF overexpression. The persistent activation of signaling pathways induced by Ras accounts for overexpression of VPF/VEGF in a significant fraction of human tumors [7, 17].

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.